Literature DB >> 7414457

Results of extended resection of tumors involving the cervical part of the trachea.

J J Terz, L D Wagman, R E King, P Brown, J P Neifeld, W Lawrence.   

Abstract

Extended resection of the trachea with construction of a mediastinal tracheostomy was performed upon 21 patients with primary or recurrent carcinoma involving the cervical part of the trachea. In 12 patients, major complications developed, and eight died of these complications. Necrosis of skin flaps and tracheal wall, leading to sepsis of the mediastinum and rupture of major vessels, were the two most common complications and causes of death. Three patients remained free of disease for 143, 77 and 48 months. A review of this experience suggests that this procedure should be limited to patients witha tumor localized to the cervical portion of the trachea and that well vascularized skin flaps--myocutaneous flaps--should be used to resurface the mediastinum and base of the neck as a means of preventing most of the complications reported in this investigation.

Entities:  

Mesh:

Year:  1980        PMID: 7414457

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  3 in total

1.  Upper esophagectomy with pharyngolaryngectomy for esophageal carcinoma at the cervicothoracic junction.

Authors:  H Fujita; T Kakegawa; Y Inoue; H Yamana; G Shirouzu; T Minami; Y Tai
Journal:  Jpn J Surg       Date:  1991-11

2.  A new method of anterior mediastinal tracheostomy following resection of cervical esophagus and the larynx: report of a case.

Authors:  A Kimura; Y Nimura; N Hayakawa; A Yasui; S Torii
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

Review 3.  Guidelines for Tracheostomy From the Korean Bronchoesophagological Society.

Authors:  Inn-Chul Nam; Yoo Seob Shin; Woo-Jin Jeong; Min Woo Park; Seong Yong Park; Chang Myeon Song; Young Chan Lee; Jae Hyun Jeon; Jongmin Lee; Chang Hyun Kang; Il-Seok Park; Kwhanmien Kim; Dong Il Sun
Journal:  Clin Exp Otorhinolaryngol       Date:  2020-07-29       Impact factor: 3.372

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.